Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals

J Infect Dis. 1995 Mar;171 Suppl 1:S50-2. doi: 10.1093/infdis/171.supplement_1.s50.

Abstract

The safety and immunogenicity of an inactivated hepatitis A vaccine (HM175) were evaluated in 151 seronegative health professionals (age range, 21-65 years; mean, 30). A 720-ELISA unit dose was administered to 78 vaccinees at 0, 1, and 6 months and to 73 vaccinees at 0, 1, and 12 months. Seroconversion rates were 90% in both groups 1 month after the first inoculation and 99% and 100%, respectively, 1 month after the second inoculation. Geometric mean antibody titers (GMTs) 1 month after the third inoculation were highest in the group vaccinated at 0, 1, and 12 months. GMTs were higher in women than in men. The vaccine was well tolerated; the most frequent side effect was transient soreness at the site of inoculation. No serious adverse reactions were observed. Thus, HM175 inactivated hepatitis A vaccine is safe and highly immunogenic.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Female
  • Health Personnel
  • Hepatitis A Antibodies
  • Hepatitis A Vaccines
  • Hepatitis A Virus, Human / immunology*
  • Hepatitis Antibodies / blood*
  • Humans
  • Immunization Schedule
  • Male
  • Middle Aged
  • Vaccines, Inactivated / administration & dosage
  • Vaccines, Inactivated / adverse effects
  • Vaccines, Inactivated / immunology
  • Viral Hepatitis Vaccines / administration & dosage
  • Viral Hepatitis Vaccines / adverse effects
  • Viral Hepatitis Vaccines / immunology*

Substances

  • Hepatitis A Antibodies
  • Hepatitis A Vaccines
  • Hepatitis Antibodies
  • Vaccines, Inactivated
  • Viral Hepatitis Vaccines